期刊
AUTOIMMUNITY REVIEWS
卷 21, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.autrev.2021.102931
关键词
CAR based therapies; Autoimmune diseases; Recognition domain; Target selection; Precision medicine
类别
资金
- National Natural Science Foundation of China [81870988, 82071410]
- Shanghai Municipal Science and Technology Major Project [2018SHZDZX01]
This study reviewed the developments of CAR-based therapies in autoimmune diseases and provided future perspectives on optimizing the performance of CAR-based therapies.
Chimeric antigen receptor (CAR) based therapies have been adopted as an option for treating autoimmune diseases from the field of blood malignancies by targeting immune cells or rebalancing the pro-inflammatory milieu. Important questions still remained about the efficacy and safety regarding the dynamic and complex autoimmune pathological networks. We here reviewed the emerged developments in basic, translational, and clinical studies of the CAR based therapies in a wide spectrum of autoimmune diseases. The primary goal of the study is to provide some future perspectives on how to optimize the performance of CAR based therapies. The fundamental strategy is to engineer the recognition domains in CAR products for precisely targeting the components in the pro-inflammatory milieu. The second strategy is to incorporate multiple CARs in one carrier, or use fluorescein isothiocyanate (FITC)-CAR T cells for enhancing the therapeutic efficacy. In addition, we reviewed the preclinical evidence in disease-specific context. Overall, we aim to attract more attention in the field of developing future precision CAR based therapies to tailor medial decisions in autoimmune diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据